The healthcare company has received European approval for a subcutaneous version of its lupus treatment Saphnelo, providing patients with a new self-administration option.
The biopharmaceutical company announced that its HER2-directed antibody drug conjugate Enhertu has been approved in the US for the first-line treatment of HER2-positive metastatic breast cancer.
The pharmaceutical company has reported a change in major shareholding, with The Capital Group Companies, Inc. reducing its stake in the business.
The healthcare company announced that its cancer drug Imfinzi has been approved in the US for the treatment of early-stage gastric and gastroesophageal cancers.
The pharmaceutical company plans a major $2 billion investment to expand its manufacturing capabilities in Maryland, supporting 2,600 jobs.
The biopharmaceutical company has received US approval for its Koselugo drug to treat a rare genetic condition in adults.
The pharmaceutical company has received a notification from a major shareholder regarding their shareholding position.
The CFO of the pharmaceutical company has sold a portion of their American Depositary Shares.
The biopharmaceutical company announces its CEO has gifted shares to family members.
The biopharmaceutical company reported strong 9M 2025 results, with total revenue up 10% and core EPS up 15% compared to the prior year period, beating market expectations.